T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells

Roberto Silvestri1,2, Perla Pucci1, Erik Venalainen3

  • 1School of Life Health and Chemical Sciences, The Open University, Milton Keynes, UK.

The Prostate
|July 24, 2019
PubMed
Abstract

Insights

T-type calcium channels (TTCCs) are upregulated in advanced prostate cancer (PCa) and linked to poorer prognosis. Inhibiting TTCCs reduced PCa cell proliferation and survival, suggesting TTCCs as potential therapeutic targets for advanced PCa.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Androgen deprivation therapy (ADT) is standard for metastatic prostate cancer (PCa).
  • Prostate cancer can evolve into incurable castration-resistant (CRPC) or neuroendocrine (NEPC) forms after ADT.
  • The role of T-type calcium channels (TTCCs) in PCa progression remains unexplored.

Purpose of the Study:

  • To investigate the expression, copy number variants (CNV), and prognostic significance of TTCCs in prostate cancer.
  • To evaluate the effect of TTCC inhibition on prostate cancer cell proliferation and survival.

Main Methods:

  • Analysis of TTCC expression and CNV in clinical PCa datasets (Oncomine, cBioPortal).
  • Assessment of TTCC expression in PCa cell lines.
  • Inhibition of TTCCs using pharmacological agents and small interfering RNA (siRNA).
  • Measurement of cell proliferation (MTT assay) and survival (caspase assay).

Main Results:

  • TTCCs were upregulated in PCa with androgen receptor (AR) mutations.
  • Higher CNV rates correlated with PCa progression.
  • Elevated expression of the TTCC isoform CACNA1G predicted worse outcomes in early-stage PCa.
  • TTCC inhibition decreased PC-3 cell proliferation and survival.

Conclusions:

  • TTCCs are overexpressed in advanced PCa and associated with poor prognosis.
  • Inhibition of TTCCs demonstrates potential therapeutic value in advanced PCa by reducing cell proliferation and survival.

Related Concept Videos

Types of Receptors: Cell Surface Receptors01:28

Types of Receptors: Cell Surface Receptors

Cell-surface receptors, also known as transmembrane receptors, are cell surface, membrane-anchored (integral) proteins that bind to external ligand molecules. This type of receptor spans the plasma membrane and performs signal transduction, converting an extracellular signal into an intracellular signal. Ligands that interact with cell-surface receptors do not have to enter the cell that they affect. Cell-surface receptors are also called cell-specific proteins or markers because they are...
26.8K
Types of Receptors: Internal Receptors01:07

Types of Receptors: Internal Receptors

Many cellular signals are hydrophilic and cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind intracellular receptors that reside within the cell cytoplasm or nucleus. Many mammalian steroid hormones and nitric oxide (NO) gas use this cell signaling mechanism.
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
31.6K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
462
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.2K
Ion Channels01:19

Ion Channels

The movement of ions like sodium, potassium, and calcium into and out of the cell is essential to maintain the electrochemical gradient in living cells. The ion channels—a class of membrane transport proteins—help maintain this ionic gradient for the smooth functioning of physiological activities such as maintaining cell size and volume, conducting nerve impulses, and gas and nutrient exchange.
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...
91.2K